BioHarvest Sciences (NASDAQ: BHST) joins Canaccord 46th Growth Conference
Rhea-AI Filing Summary
BioHarvest Sciences Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, held August 11-13, 2026. Chief Executive Officer Zaki Rakib is scheduled to deliver a company presentation on Wednesday, August 12, 2026, at 1:00 p.m. and will also hold one-on-one investor meetings on August 11-12.
The presentation will be available via a publicly accessible live webcast for online pre-registrants, while in-person attendance requires conference registration. BioHarvest describes itself as a leader in Botanical Synthesis, operating both as a CDMO for plant-based compounds and as a developer of proprietary nutraceutical health and wellness products.
Positive
- None.
Negative
- None.
Key Figures
Conference dates: August 11-13, 2026
Presentation time: 1:00 p.m., August 12, 2026
One-on-one meeting dates: August 11-12, 2026
3 metrics
Conference dates
August 11-13, 2026
Dates of the Canaccord Genuity 46th Annual Growth Conference in Boston
Presentation time
1:00 p.m., August 12, 2026
Scheduled time for BioHarvest CEO company presentation
One-on-one meeting dates
August 11-12, 2026
Period when CEO will participate in investor one-on-one meetings
Key Terms
Botanical Synthesis, contract development and manufacturing organization (CDMO), nutraceutical, forward-looking statements
4 terms
Botanical Synthesis technical
"BioHarvest is a leader in Botanical Synthesis, leveraging its patented technology platform"
Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.
contract development and manufacturing organization (CDMO) technical
"as a contract development and manufacturing organization (CDMO) on behalf of customers"
A contract development and manufacturing organization (CDMO) is a company that develops and produces drugs, vaccines or other medical products for other firms, handling steps from formulation and testing to large-scale manufacturing and quality control. Investors care because CDMOs function like outsourced specialized factories and development partners: their revenue grows when many clients need production capacity or development expertise, so their performance signals broader industry demand and is tied to regulatory approvals and client programs.
nutraceutical medical
"creator of proprietary nutraceutical health and wellness products based on its botanical synthesis"
A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.
forward-looking statements regulatory
"This news release may contain forward-looking statements within the meaning of applicable"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did BioHarvest Sciences (BHST) announce regarding the Canaccord Genuity 46th Annual Growth Conference?
BioHarvest Sciences announced that CEO Zaki Rakib will present at Canaccord Genuity’s 46th Annual Growth Conference in Boston. The company will deliver a formal presentation and participate in one-on-one investor meetings, highlighting its Botanical Synthesis platform and product strategy.
When will BHST’s CEO present at the Canaccord Genuity 46th Annual Growth Conference?
BHST’s CEO, Zaki Rakib, is scheduled to present on Wednesday, August 12, 2026, at 1:00 p.m. The session is part of the multi-day conference running August 11-13, 2026, and is described as a company presentation format.
How can investors access BioHarvest Sciences (BHST) presentation online?
Investors can access the BHST presentation via a publicly accessible live webcast using the provided URL. Online access requires pre-registration, while in-person participation also requires conference registration through Canaccord Genuity’s standard conference process.
What one-on-one investor meeting opportunities does BHST offer at the conference?
BioHarvest’s CEO will conduct one-on-one investor meetings from August 11-12, 2026. Institutional investors attending the conference may request meetings with the company through their Canaccord Genuity representative, providing direct access to management alongside the formal presentation.
What is BioHarvest Sciences (BHST) core business focus?
BioHarvest focuses on Botanical Synthesis, using a patented platform to grow plant-based compounds without cultivating the whole plant. It operates as a CDMO for novel plant-based molecules and develops proprietary nutraceutical health and wellness products based on this technology.
Where is the Canaccord Genuity 46th Annual Growth Conference featuring BHST held?
The conference is held at the InterContinental Hotel in Boston, Massachusetts. BioHarvest’s in-person presentation takes place in the venue’s Abigail Adams C room, with both in-person and webcast participation options for interested investors.